| abstract |
The invention relates to humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), the CAR being able to be expressed in a human cell so that the CAR specifically binds to HLA-A2. The invention also provides CARs that comprise the humanized anti-HLA-A2 antibodies. The invention also provides modified cells comprising antibodies and CARs, as well as methods of using such modified cells. |